share_log

Tharimmune | DEF 14A: Definitive information statements

Tharimmune | DEF 14A: Definitive information statements

Tharimmune | DEF 14A：股東委託書決議
美股sec公告 ·  03/22 05:27
牛牛AI助理已提取核心訊息
Tharimmune, Inc. announced the filing of a definitive proxy statement (DEF 14A) with the U.S. Securities and Exchange Commission, detailing the upcoming annual meeting of stockholders scheduled for May 14, 2024. The meeting will address several key proposals, including the election of five board members, ratification of the independent accounting firm Rosenberg Rich Baker Berman P.A. for the fiscal year ending December 31, 2024, and approval of the Amended and Restated 2023 Omnibus Equity Incentive Plan. Additionally, the board will seek discretionary authority to amend the company's Certificate of Incorporation to effect a reverse stock split of the issued and outstanding shares of common stock, with a ratio range from 1-for-2 up to 1-for-50, to be completed by May 14, 2025. The reverse stock split...Show More
Tharimmune, Inc. announced the filing of a definitive proxy statement (DEF 14A) with the U.S. Securities and Exchange Commission, detailing the upcoming annual meeting of stockholders scheduled for May 14, 2024. The meeting will address several key proposals, including the election of five board members, ratification of the independent accounting firm Rosenberg Rich Baker Berman P.A. for the fiscal year ending December 31, 2024, and approval of the Amended and Restated 2023 Omnibus Equity Incentive Plan. Additionally, the board will seek discretionary authority to amend the company's Certificate of Incorporation to effect a reverse stock split of the issued and outstanding shares of common stock, with a ratio range from 1-for-2 up to 1-for-50, to be completed by May 14, 2025. The reverse stock split aims to increase the per-share price of Tharimmune's common stock to comply with Nasdaq's minimum bid price requirement. The board may also arrange for the disposition of fractional shares by rounding up to the next whole number. The meeting will also cover other business as may properly come before the meeting or any adjournment or postponement thereof.
Tharimmune, Inc.宣佈向美國證券交易委員會提交最終委託書（DEF 14A），詳細說明了定於2024年5月14日舉行的年度股東大會。會議將討論幾項關鍵提案，包括選舉五名董事會成員，批准獨立會計師事務所羅森伯格·裏奇·貝克·伯曼會計師事務所截至2024年12月31日的財年，以及批准經修訂和重述的2023年綜合股權激勵計劃。此外，董事會將尋求修改公司註冊證書的自由裁量權，以對已發行和流通的普通股進行反向股票拆分，比例從1比2到1比50不等，將在2025年5月14日之前完成。反向股票拆分旨在提高Tharimmune普通股的每股價格，以符合納斯達克的最低出價要求。董事會還可以通過四捨五入到下一個整數來安排部分股份的處置。會議還將涵蓋在會議或任何休會或延期之前適當處理的其他事項。
Tharimmune, Inc.宣佈向美國證券交易委員會提交最終委託書（DEF 14A），詳細說明了定於2024年5月14日舉行的年度股東大會。會議將討論幾項關鍵提案，包括選舉五名董事會成員，批准獨立會計師事務所羅森伯格·裏奇·貝克·伯曼會計師事務所截至2024年12月31日的財年，以及批准經修訂和重述的2023年綜合股權激勵計劃。此外，董事會將尋求修改公司註冊證書的自由裁量權，以對已發行和流通的普通股進行反向股票拆分，比例從1比2到1比50不等，將在2025年5月14日之前完成。反向股票拆分旨在提高Tharimmune普通股的每股價格，以符合納斯達克的最低出價要求。董事會還可以通過四捨五入到下一個整數來安排部分股份的處置。會議還將涵蓋在會議或任何休會或延期之前適當處理的其他事項。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。